A Pilot Study of Cystic Volume Reduction by Foam Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease

ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis. Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces further growth of cysts but does not reduce the cyst burden. Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects. From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!

A Pilot Study of Cystic Volume Reduction by Foam Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease

About us

Project Description

A Pilot Study of Cystic Volume Reduction by Foam Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease

Background

Description

Team

No items found

Project Advisory Committee

Prof
Edyta Marcon
She/Her
Prof
Joseph Ferenbok
He/Him
Prof
Joseph Ferenbok
He/Him

Team members

Test Student
Student PI
Read More

Project Advisory Committee (PAC)

TRP Supervisors

Joseph talkking to students.
Joseph Ferenbok
TRP Supervisor
Dr. Edyta Marcon with her 3 dogs
Edyta Marcon
TRP Supervisor
Back to capstones

Explore

Join our mailing list

Subscribe

Don’t miss our latest program updates, events, stories, and more.

Contact Us

  • Room 120
  • Old Administration Building
  • University of Toronto
  • 263 McCaul, Toronto, ON
  • Canada, M5T 1W7
Apply
Book Consult

Copyright © 2024 — MHSc in Translational Research. All Rights Reserved